Accelerating Covid-19 Antibody Discovery Through Industry-Academia Consortium
The BioIndustry Association’s Antibody Taskforce is a world-leading consortium of biotech companies, charities and academia experts based across the UK who share a joint commitment to help fight the COVID-19 pandemic. Contributing their expertise and specialist resources, the team is working together to rapidly identify the most promising antibodies with the potential to positively impact the treatment of those affected by this devastating virus.

The goal of the Taskforce is to develop an antibody-based treatment for patients with COVID-19, which could also potentially work as a preventative therapy for high-risk individuals and complement the current vaccination strategy. As part of a global hub for the life sciences, the UK BIA Antibody Taskforce wants to truly make a difference to people’s lives.
Date: 6 April 2021, 12:00 (Tuesday, -2nd week, Trinity 2021)
Venue: Zoom
Speakers: Jane Osbourn OBE, CSO (Alchemab), Paul Kellam, VP infectious diseases and vaccines (Kymab)
Organising department: Medical Sciences Office
Organisers: Elodie Siney (BioEscalator), Sheena Lee (MSD Business Partnerships Office), Medical Sciences Division Business Partnerships Office (University of Oxford)
Organiser contact email address:
Hosts: Elodie Siney (BioEscalator), Sheena Lee (MSD Business Partnerships Office)
Part of: Industry Insight Seminar Series
Booking required?: Required
Booking url:
Cost: Free
Audience: Members of the University of Oxford and the Biotech/Pharma industry
Editors: Sheena Lee, Elodie Siney